Portal Hypertension

Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.

Also Known As:

Hypertension, Portal; Cruveilhier Baumgarten Disease; Cruveilhier Baumgarten Syndrome; Disease, Cruveilhier-Baumgarten; Portal Hypertensions; Syndrome, Cruveilhier-Baumgarten; Cruveilhier-Baumgarten Disease; Cruveilhier-Baumgarten Syndrome

Networked: 7261 relevant articles (506 outcomes, 713 trials/studies)

Relationship Network

Disease Context: Research Results

Digestive System Diseases: 1042
- Liver Diseases: 41660
  - Portal Hypertension: 7261

Related Diseases

1.	Fibrosis (Cirrhosis)
2.	Hemorrhage
3.	Liver Cirrhosis (Hepatic Cirrhosis)
4.	Varicose Veins (Varicose Vein)
5.	Esophageal and Gastric Varices (Esophageal Varices)

Experts

1.	Bosch, Jaime: 73 articles (08/2022 - 02/2002)
2.	Trebicka, Jonel: 58 articles (10/2022 - 06/2005)
3.	Reiberger, Thomas: 51 articles (10/2022 - 07/2011)
4.	Lee, Fa-Yauh: 41 articles (12/2021 - 01/2002)
5.	Lin, Han-Chieh: 41 articles (01/2021 - 01/2002)
6.	Trauner, Michael: 40 articles (10/2022 - 07/2011)
7.	Lee, Shou-Dong: 39 articles (04/2020 - 01/2002)
8.	Abraldes, Juan G: 37 articles (01/2022 - 06/2002)
9.	Mandorfer, Mattias: 35 articles (10/2022 - 05/2013)
10.	Berzigotti, Annalisa: 34 articles (10/2022 - 03/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Portal Hypertension:

1.	Propranolol (Inderal)FDA LinkGeneric 07/01/1999 - "The purpose of this study was to evaluate safety and efficacy of propranolol in the management of portal hypertension in the pediatric population. " 09/01/1991 - "Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats." 12/01/2007 - "We conducted this study to determine the effect of propranolol on portal hypertension and the optimal required dose in Korean cirrhotic patients. " 03/01/2003 - "The study was initiated in 53 patients with portal hypertension, of whom 14 were withdrawn because of adverse effects of propranolol. " 05/01/1991 - "This study was aimed at investigating the effects of propranolol on esophageal variceal pressure in patients with portal hypertension. "
2.	Octreotide (Sandostatin)FDA LinkGeneric 02/01/2001 - "Objective: Recent studies have demonstrated octreotide as being potentially beneficial for the long-term management of cirrhotic portal hypertension. " 04/01/1993 - "We conclude that SMS 201-995 is useful for the treatment of portal hypertension because of its effect of reducing portal pressure with mild changes in systemic hemodynamics. " 04/01/2012 - "Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension." 11/01/1996 - "The aim of the present study was to investigate whether chronic administration of octreotide can increase vascular responsiveness in rats with portal hypertension. " 11/01/1992 - "Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study."
3.	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/01/2005 - "Our study demonstrates that increased ET and nitric oxide metabolism is associated with the hemodynamic alterations induced by portal hypertension." 11/01/2002 - "This study demonstrated that the increased nitric oxide metabolism is associated with the haemodynamic alterations induced by portal hypertension." 11/01/2019 - "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances. " 03/21/2013 - "Current concepts on the role of nitric oxide in portal hypertension." 05/01/2012 - "It can also augment nitric oxide (NO) production, which plays a crucial role in the pathogenesis of portal hypertension and modulation of porto-systemic collaterals. "
4.	4-(3-chlorophenylsulfanyl)piperidineIBA 06/10/2021 - "From a different perspective, VCTE may be effective in identifying clinically significant portal hypertension (CSPH). " 12/01/2015 - "Hepatic vein pressure gradient (HVPG) is the gold standard for diagnosing clinically significant portal hypertension (CSPH). " 12/01/2022 - "In this study, we aim to assess the diagnostic performance of 2D/3D MR elastography (MRE) and shear wave elastography (SWE) measures of liver and spleen stiffness (LS and SS) and spleen volume, to noninvasively diagnose clinically significant portal hypertension (CSPH) using HVPG measurement as the reference. " 09/01/2019 - "Objective: This study was aimed to evaluate the correlation between clinically significant portal hypertension (CSPH) and postoperative complications and risk predictors of postoperative complications. " 01/28/2017 - "To study the diagnostic accuracy of transient elastography (TE) for detecting clinically significant portal hypertension (CSPH) in Indian patients with cirrhotic portal hypertension. "
5.	TerlipressinIBA 10/01/2023 - "This study provides robust evidence suggesting that continuous terlipressin infusion may be superior to intermittent infusions in reducing the risk of rebleeding, treatment failure, and adverse effects in patients with portal hypertension. " 07/01/2013 - "This study aims to compare the effects of bolus and continuous infusion of terlipressin on systemic and hepatic hemodynamics in patients with portal hypertension. " 01/01/1993 - "This study suggests that terlipressin might further reduce portal pressure in patients with portal hypertension treated with beta-blockers." 10/01/2023 - "Continuous vs. intermittent terlipressin infusion for portal hypertension: a systematic review and meta-analysis." 01/01/2020 - "Rapid reversal of hyponatraemia in a patient with non-cirrhotic portal hypertension treated with terlipressin."
6.	Vasopressins (Vasopressin)IBA 09/01/2001 - "F-180 has been proposed as a new vasopressin analogue for the treatment of portal hypertension. " 11/01/1995 - "Response of blood flow to vasopressin in the collateral left gastric vein in patients with portal hypertension." 07/01/1991 - "Effects of vasopressin on gastric mucosal blood flow in portal hypertension." 04/01/1991 - "Ten to twelve days after the induction of chronic portal hypertension, the responsiveness of the small intestinal circulation to cumulative doses of vasopressin was evaluated using an isolated pump-perfused small intestinal preparation. " 07/01/1987 - "Portal pressure, arterial pressure, and regional and systemic blood flows were measured in a rat model of portal hypertension receiving placebo or vasopressin infusion. "
7.	InterferonsIBA 02/01/2012 - "Long-term low-dose maintenance pegylated interferon may prevent decompensation in cirrhotic patients with portal hypertension: are we there yet?" 07/01/2006 - "Does interferon improve portal hypertension?" 10/01/2016 - "Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension." 10/01/2016 - "We aimed to investigate the impact of sustained virologic response (SVR) to interferon (IFN)-free therapies on portal hypertension in patients with paired hepatic venous pressure gradient (HVPG) measurements. " 07/14/2017 - "Sustained viral response (SVR) after interferon-based regimens has been associated with improvement in liver function, fibrosis and portal hypertension in a significant proportion of patients, although a point of no return seems to exist from which viral elimination is no longer capable of preventing portal hypertension progression and liver decompensation. "
8.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 11/01/2020 - "The efficacy of somatostatin in altering splanchnic hemodynamics in cirrhotic portal hypertension is still controversial. " 08/15/2003 - "Despite universal use of somatostatin, the cellular and biochemical mechanisms of its effects in portal hypertension are relatively poorly studied and remain incompletely understood. " 08/15/2003 - "Pharmacological rationale for the use of somatostatin and analogues in portal hypertension." 06/01/2002 - "Somatostatin and analogues in portal hypertension." 02/01/2000 - "Effects of somatostatin on splanchnic hemodynamics in cirrhotic patients with portal hypertension."
9.	Lysergic Acid Diethylamide (LSD)IBA 11/01/2020 - "A total of 118 patients with cirrhotic portal hypertension who underwent LSD were included in this study. " 02/01/2015 - "From June 2012 to June 2014, LSD was performed on 138 patients with portal hypertension. " 10/01/2022 - "The aim of this study was to evaluate whether RSD is feasible and safe for patients with cirrhotic portal hypertension and whether RSD is superior to laparoscopic splenectomy and azygoportal disconnection (LSD). " 11/01/2023 - "This study explored whether laparoscopic splenectomy and azygoportal disconnection (LSD) can reduce the risk of HCC among patients with hepatitis B virus (HBV)-related cirrhotic portal hypertension (CPH). " 01/01/2023 - "The aim of this study was to explore whether laparoscopic splenectomy and azygoportal disconnection (LSD) decreases the risk of HCC for patients with cirrhotic portal hypertension (CPH). "
10.	Antiviral Agents (Antivirals)IBA 08/02/2022 - "Antiviral treatment is effective in improving indirect signs of hepatic synthesis and portal hypertension. " 04/01/2022 - "The changes in portal hypertension after achieving a sustained viral response (SVR) by direct-acting antivirals (DAAs) have not been fully elucidated. " 01/01/2021 - "Nonselective β-blockers improve decompensation-free survival in viremic hepatitis C virus compensated cirrhotic patients with clinically significant portal hypertension, but their protective role after sustained virological response by direct-acting antiviral (DAA) is undefined. " 02/01/2020 - "Direct-acting antivirals (DAAs) show high efficacy and safety in HCV-cirrhotic patients, but most maintain clinically significant portal hypertension after sustained virological response (SVR). " 02/01/2004 - "In HC patients with portal hypertension syndrome progress and against the background of increased blood serum IFN-alpha concentration its antiviral activity decreases. "

Therapies and Procedures

1.	Transjugular Intrahepatic Portasystemic Shunt 10/01/2023 - "TIPS placement is the most effective treatment of portal hypertension. " 01/01/2022 - "TIPS implantation is a highly effective treatment for portal hypertension. " 03/01/1994 - "TIPS which brings about an immediate marked reduction in the portal pressure appears to be promising as a new treatment for portal hypertension." 01/01/2019 - "Spleen stiffness is superior to liver stiffness and Child-Pugh score as a non-invasive surveillance tool for evaluating patients with clinically significant portal hypertension (HVPG ≥ 10 mmHg) prior to TIPS." 01/21/2010 - "TIPS procedure is effective in lowering portal pressure in patients with portal hypertension and improves body composition without significant changes in metabolic parameters."
2.	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/01/2020 - "Transjugular intrahepatic portosystemic shunt has been established as an effective treatment for complicated portal hypertension. " 04/01/2018 - "Transjugular intrahepatic portosystemic shunt is effective in treatment of portal hypertension. " 01/01/1994 - "Transjugular intrahepatic portosystemic shunts are effective in lowering portal pressure and controlling complications of portal hypertension. " 10/06/1989 - "The transjugular intrahepatic portosystemic shunt is effective in the treatment of portal hypertension and might become an alternative to shunt surgery." 01/01/2021 - "Surgical portosystemic shunts are safe and effective for symptom relief in selected patients with portal hypertension. "
3.	Therapeutics 02/01/2017 - "An individualized laparoscopic therapy was beneficial for different state of selected cirrhotic patients with portal hypertension with or without HCC." 04/01/2007 - "The good results of this therapy were associated with its effect in decreasing portal hypertension of the patients." 07/01/1989 - "We stress that although this therapy is effective for the child with portal hypertension, the incidence of complications might be high in patient with severely damaged liver function. " 03/01/2006 - "It is effective for treating the complications of portal hypertension and provides effective portal blood flow that other medical and surgical therapies do not. " 08/01/2003 - "myr-Akt gene therapy restored Akt activation and NO production in the cirrhotic liver, suggesting that this therapy may be useful for the treatment of portal hypertension."
4.	Splenectomy 01/01/2004 - "Esophagogastric devascularization and splenectomy promote a significant reduction of the elevated portal pressure and flow in schistosomal portal hypertension. " 11/01/2018 - "Laparoscopic splenectomy and azygoportal disconnection with periodical postoperative endoscopy is safe and effective for reducing the EVR rate in cirrhotic portal hypertension." 06/01/2015 - "Esophagogastric devascularization without splenectomy in portal hypertension: safe and effective?" 12/01/2018 - "This study aimed to compare the efficacy of laparoscopic splenectomy plus selective pericardial devascularization (LSSD) and open splenectomy and nonselective pericardial devascularization (OSD) in patients with portal hypertension. " 12/01/2018 - "Comparison of Efficacy of Laparoscopic and Open Splenectomy Combined With Selective and Nonselective Pericardial Devascularization in Portal Hypertension Patients."
5.	Liver Transplantation 01/01/2017 - "With the advent of the new IFN-free regimens, highly effective and safe even in those historically considered "difficult to treat and cure patients," additional benefits have been documented in patients treated at advanced stages of disease, including improvement in liver function with hepatic "recompensation," reduction of portal hypertension, and eventually avoidance of liver transplantation. " 02/01/2012 - "Liver transplantation was strikingly effective for treating the clinical symptoms attributable to portal hypertension. " 09/01/2015 - "The outcomes of liver resection were improved while liver transplantation was performed for the patients with suspicious portal hypertension. " 04/01/2013 - "One patient required liver transplantation for de novo symptoms of portal hypertension 4 years after primary symptoms had been cured by HAE. " 08/01/2023 - "This study demonstrates that non-cirrhotic portal hypertension or obliterative portal venopathy is the predominant hepatic pathophysiology in adult CF patients requiring liver transplantation. "